NGM Biopharmaceuticals Secures $105,999,996 Series E Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3cc6867c-0497-404d-9185-75ec0a45aee2 -
Date
3/26/2015 -
Company Name
NGM Biopharmaceuticals -
Mailing Address
630 Gateway Blvd South San Francisco, CA 94080 USA -
Company Description
NGM is a privately-held drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity, muscle wasting and other cardiometabolic diseases. -
Website
http://www.ngmbio.com -
Transaction Type
Venture Equity -
Transaction Amount
$105,999,996 -
Transaction Round
Series E -
Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities. -
M&A Terms
-
Venture Investor
